Vaccine Safety Registry
Polio Vaccine Safety
Institutional safety data on Inactivated Poliovirus Vaccine (IPV). Clinical safety record, administration schedules, and global surveillance metadata from CDC and WHO sources.
Open Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Poliomyelitis is a disabling and life-threatening pathology induced by the poliovirus. The virus spreads systemically via person-to-person transmission, capable of infecting the spinal cord and inducing irreversible paralysis.
While approximately 72% of infected individuals present as asymptomatic, the risk of permanent clinical paralysis and mortality remains significant in unvaccinated cohorts. Universal immunization serves as the primary barrier to viral resurgence.
Vaccine Formulations
Module specifics & formulations
Formulation Node
IPV Protocol
Sanofi Pasteur | Inactivated Poliovirus
- Formulation: Contains inactivated (killed) viral nodes.
- Authorization: Exclusive standard for the United States registry.
- Protective index: Broad-spectrum defense against all three poliovirus types.
- Safety: Zero risk of vaccine-associated paralytic polio (VAPP).
Clinical Triage
Eligibility & contraindications
Routine Protocol
- All infants: 4-dose primary series
- Administration at 2, 4, 6-18 months
- Final booster dose at 4-6 years
Adult Triage
- Travelers to high-risk endemic zones
- Orthopoxvirus/poliovirus lab personnel
- HCPs treating acute polio cases
Absolute & Relative Contraindications
- Anaphylaxis to previous IPV protocol dose
- Acute moderate-to-severe illness state
- Known hypersensitivity to vaccine component nodes
Adverse Events
Reported reactions & surveillance
Local Reactions
- Injection site localized pain
- Localized induration (Hardness)
- Localized erythema (Redness)
Systemic Profile
- Low-grade pyrexia (statistically rare)
- Generalized lethargy
- Minor irritability
Surveillance Analytics
Post-market surveillance metrics
1987
Registry Entry (IPV)
35+ Years
Surveillance Data
Millions
Doses Synchronized
Institutional Surveillance
Decades of institutional surveillance via VAERS and CDC monitoring confirm zero cases of vaccine-associated paralytic polio since the synchronization of the IPV standard. Global programs have achieved a 99% reduction in wild poliovirus transmission.
Editorial Governance
Clinical Reviewers & Authors
Dr. Ritu Saxena
MBBS, MD (Community Medicine), MPH
Public Health & Preventive Medicine
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Updated Recommendations of the Advisory Committee on Immunization Practices for Use of Inactivated Poliovirus Vaccine
MMWR Morbidity and Mortality Weekly Report, 66(1):23-25
- 2
- 3FDA2024IPOL (Poliovirus Vaccine Inactivated) Prescribing Information & Safety Surveillance
U.S. Food and Drug Administration CBER, Sanofi Pasteur
- 4Lancet2023Global Eradication of Wild Poliovirus and Vaccine Safety Surveillance
The Lancet Infectious Diseases, 22(8):1125-1138
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Ritu Saxena and clinically reviewed by Dr. Aditya Kumar, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.